EUVIMEDEUVIMED entdecken
Open Access

Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer

Yonina R Murciano-Goroff iD, Angela B-Y Hui, Jose A Araujo Filho iD, Emily G Hamilton iD, Jacob J Chabon iD, Everett J Moding iD, Rene F Bonilla, Emily S Lebow iD, Daniel Gomez, Andreas Rimner iD, Michelle S Ginsberg iD, Michael Offin iD und 13 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Yonina R Murciano-Goroff und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Small cell lung cancer (SCLC) is characterized by rapid progression after platinum resistance. Circulating tumor (ctDNA) dynamics early in treatment may help determine platinum sensitivity. MATERIALS AND METHODS Serial plasma samples were collected from patients receiving platinum-based chemotherapy for SCLC on the first 3 days of cycle one and on the first days of subsequent cycles with paired samples collected both before and again after infusions. Tumor-informed plasma analysis was carried out using CAncer Personalized Profiling by deep Sequencing (CAPP-Seq). The mean variant allele frequency (VAF) of all pretreatment mutations was tracked in subsequent blood draws and correlated with radiologic response. RESULTS ctDNA kinetics were assessed in 122 samples from 21 patients. Pretreatment VAF did not differ significantly between patients who did and did not respond to chemotherapy (mean 22.5% v 4.6%, P = .17). A slight increase in ctDNA on cycle 1, day 1 immediately post-treatment was seen in six of the seven patients with available draws (fold change from baseline: 1.01-1.44), half of whom achieved a response. All patients who responded had a >2-fold decrease in mean VAF on cycle 2 day 1 (C2D1). Progression-free survival (PFS) and overall survival (OS) were significantly longer in patients with a >2-fold decrease in mean VAF after one treatment cycle (6.8 v 2.6 months, log-rank P = .0004 and 21.7 v 6.4 months, log rank P = .04, respectively). CONCLUSION A >2-fold decrease in ctDNA concentration was observed by C2D1 in all patients who were sensitive to platinum-based therapy and was associated with longer PFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNASmall Cell Lung CarcinomaLung NeoplasmsHumansMaleFemaleMiddle AgedAgedDrug Resistance, NeoplasmAdultPlatinumAntineoplastic Agents

Substanzen

Circulating Tumor DNAPlatinumAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY.
  • Stanford Cancer Institute, Stanford University, Stanford, CA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiation Oncology, Stanford University, Stanford, CA.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Yonina R Murciano-Goroff, Jose A Araujo Filho, Emily G Hamilton, Jacob J Chabon, Everett J Moding, Emily S Lebow, Andreas Rimner, Michelle S Ginsberg, Michael Offin, Ritika Kundra, Larry Norton, Pedram Razavi, Alexander Drilon, David R Jones, Charles M Rudin, Ash A Alizadeh, Bob T Li, Maximilian Diehn

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Murciano-Goroff, Y. R., Hui, A. B., Araujo Filho, J. A., Hamilton, E. G., Chabon, J. J., Moding, E. J., Bonilla, R. F., Lebow, E. S., Gomez, D., Rimner, A., Ginsberg, M. S., Offin, M., Kundra, R., Allaj, V., Norton, L., Reis-Filho, J. S., Razavi, P., Drilon, A., Jones, D. R., …, & Diehn, M. (2024). Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.24.00216

Vancouver

Murciano-Goroff YR, Hui AB, Araujo Filho JA, Hamilton EG, Chabon JJ, Moding EJ, et al. Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.24.00216

BibTeX
@article{MurcianoGoroff2024,
  author = {Murciano-Goroff, Yonina R and Hui, Angela B-Y and Araujo Filho, Jose A and Hamilton, Emily G and Chabon, Jacob J and Moding, Everett J and Bonilla, Rene F and Lebow, Emily S and Gomez, Daniel and Rimner, Andreas and Ginsberg, Michelle S and Offin, Michael and Kundra, Ritika and Allaj, Viola and Norton, Larry and Reis-Filho, Jorge S and Razavi, Pedram and Drilon, Alexander and Jones, David R and Isbell, James M and Lai, W Victoria and Rudin, Charles M and Alizadeh, Ash A and Li, Bob T and Diehn, Maximilian},
  title = {Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00216}
}
Kostenlos starten →